What is ZyVersa Therapeutics Inc's earnings per share (EPS)?

ZyVersa Therapeutics Inc (ZVSA) reported diluted earnings per share of $-4.18 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ZyVersa Therapeutics Inc Financials

ZVSA

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows ZyVersa Therapeutics Inc (ZVSA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

ZyVersa Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.20x

For every $1 of reported earnings, ZyVersa Therapeutics Inc generates $0.20 in operating cash flow (-$5.1M OCF vs -$25.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-49.7x

ZyVersa Therapeutics Inc earns $-49.7 in operating income for every $1 of interest expense (-$25.5M vs $513K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$25.5M

YoY-179.1%

ZyVersa Therapeutics Inc's EBITDA was -$25.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 179.1% from the prior year.

Net Income

-$25.0M

YoY-165.1%

ZyVersa Therapeutics Inc reported -$25.0M in net income in fiscal year 2025. This represents a decrease of 165.1% from the prior year.

EPS (Diluted)

$-4.18

ZyVersa Therapeutics Inc earned $-4.18 per diluted share (EPS) in fiscal year 2025. This represents an increase of 50.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.5M

YoY+0.0%

ZyVersa Therapeutics Inc held $1.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

ZyVersa Therapeutics Inc had 8M shares outstanding in fiscal year 2025. This represents an increase of 222.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$1.1M

YoY-37.4%

ZyVersa Therapeutics Inc invested $1.1M in research and development in fiscal year 2025. This represents a decrease of 37.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ZVSA Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	$1.1M-37.4%	$1.8M-44.5%	$3.2M-40.7%	$5.4M
SG&A Expenses	$5.7M-22.1%	$7.4M-34.4%	$11.2M+47.4%	$7.6M
Operating Income	-$25.5M-179.0%	-$9.1M+91.5%	-$107.8M-728.0%	-$13.0M
Interest Expense	-$513K-90.2%	-$270K-59149.5%	$457+100.1%	-$428K
Income Tax	-$852K-12726.5%	$7K+100.1%	-$9.5M	N/A
Net Income	-$25.0M-165.1%	-$9.4M+90.4%	-$98.3M-599.7%	-$14.0M
EPS (Diluted)	$-4.18	$-8.48	$-1089.70-109970.7%	$-0.99

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$365K-10.9%	$410K+58.4%	$259K	N/A	$436K-38.5%	$709K+38.2%	$513K	N/A
SG&A Expenses	$1.7M+6.4%	$1.6M-13.3%	$1.9M	N/A	$1.8M-10.3%	$2.0M-11.6%	$2.3M	N/A
Operating Income	-$20.8M-915.2%	-$2.0M+4.7%	-$2.1M	N/A	-$2.3M+17.6%	-$2.8M+2.6%	-$2.8M	N/A
Interest Expense	-$131K-1.0%	-$130K-8.8%	-$120K	N/A	-$132K-226856.9%	-$58+42.6%	-$101	N/A
Income Tax	-$852K	N/A	N/A	N/A	N/A	$10K	N/A	N/A
Net Income	-$19.8M-795.6%	-$2.2M+2.0%	-$2.3M	N/A	-$2.4M+13.1%	-$2.8M+2.2%	-$2.8M	N/A
EPS (Diluted)	$-2.56-456.5%	$-0.46	$-0.73	N/A	$-2.43+26.6%	$-3.31	$-4.53	N/A

ZVSA Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$348K-98.3%	$20.6M-6.9%	$22.1M-81.3%	$118.5M
Current Assets	$348K-79.7%	$1.7M-48.8%	$3.4M-47.3%	$6.4M
Cash & Equivalents	$1.5M0.0%	$1.5M-51.2%	$3.1M-46.8%	$5.9M
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$11.9M
Total Liabilities	$12.7M+5.4%	$12.1M+9.5%	$11.0M-40.4%	$18.5M
Current Liabilities	$12.7M+13.4%	$11.2M+10.2%	$10.2M+24.5%	$8.2M
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	-$12.4M-245.4%	$8.5M-23.1%	$11.1M-88.9%	$99.7M
Retained Earnings	-$137.6M-22.2%	-$112.6M-9.1%	-$103.2M-1997.4%	-$4.9M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$1.0M-94.7%	$19.6M-6.4%	$21.0M+1.9%	$20.6M+6.1%	$19.4M-0.2%	$19.5M-10.1%	$21.7M-2.1%	$22.1M
Current Assets	$996K+81.3%	$549K-74.0%	$2.1M+23.0%	$1.7M+339.5%	$390K-39.1%	$641K-77.9%	$2.9M-13.5%	$3.4M
Cash & Equivalents	$528K+632.4%	$72K-95.5%	$1.6M+5.3%	$1.5M+1145.5%	$123K+2.9%	$119K-94.1%	$2.0M-35.2%	$3.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$12.8M-5.7%	$13.5M+5.3%	$12.9M+6.4%	$12.1M-2.5%	$12.4M+14.3%	$10.8M+4.0%	$10.4M-5.5%	$11.0M
Current Liabilities	$12.8M+0.6%	$12.7M+5.7%	$12.0M+6.9%	$11.2M-2.7%	$11.5M+15.5%	$10.0M+4.3%	$9.6M-6.0%	$10.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$11.7M-292.2%	$6.1M-25.0%	$8.1M-4.5%	$8.5M+21.2%	$7.0M-18.5%	$8.6M-23.2%	$11.2M+1.3%	$11.1M
Retained Earnings	-$136.9M-16.9%	-$117.1M-1.9%	-$114.9M-2.0%	-$112.6M-1.3%	-$111.2M-2.2%	-$108.8M-2.6%	-$106.0M-2.7%	-$103.2M

ZVSA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	-$5.1M+32.3%	-$7.6M+13.3%	-$8.7M-483.5%	-$1.5M
Capital Expenditures	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A
Financing Cash Flow	$3.7M-38.1%	$6.0M-0.1%	$6.0M+219.3%	$1.9M
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$1.4M+7.5%	-$1.5M+14.1%	-$1.8M-41.2%	-$1.3M-104.3%	-$614K+67.9%	-$1.9M+49.3%	-$3.8M-35.5%	-$2.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$1.9M+10613.6%	-$18K-101.0%	$1.9M-30.4%	$2.7M+331.2%	$618K	$0-100.0%	$2.7M-38.5%	$4.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ZVSA Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A
Return on Equity	N/A	-110.5%+777.1pp	-887.6%-873.5pp	-14.1%
Return on Assets	-7172.3%-7126.6pp	-45.7%+398.8pp	-444.5%-432.7pp	-11.8%
Current Ratio	0.03-0.1	0.15-0.2	0.33-0.4	0.78
Debt-to-Equity	-1.03-2.4	1.42+0.4	1.00+0.8	0.19
FCF Margin	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-36.3%-8.5pp	-27.8%	N/A	-34.2%-2.1pp	-32.1%-6.9pp	-25.2%	N/A
Return on Assets	-1903.9%-1892.6pp	-11.3%-0.5pp	-10.8%	N/A	-12.4%+1.8pp	-14.2%-1.1pp	-13.1%	N/A
Current Ratio	0.08+0.0	0.04-0.1	0.18+0.0	0.15+0.1	0.03-0.0	0.06-0.2	0.30-0.0	0.33
Debt-to-Equity	-1.09-3.3	2.22+0.6	1.58+0.2	1.42-0.3	1.76+0.5	1.26+0.3	0.93-0.1	1.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$12.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Purple Biotech Ltd PPBT

$3.8M

Windtree Therapeutics Inc WINT

$13.8M

CDT Equity CDT

$19.9M

Lipella Pharmaceuticals Inc LIPO

$11.8M

Salarius Pharmaceuticals Inc SLRX

$4.9M

Frequently Asked Questions

Is ZyVersa Therapeutics Inc profitable?

No, ZyVersa Therapeutics Inc (ZVSA) reported a net income of -$25.0M in fiscal year 2025.

What is ZyVersa Therapeutics Inc's EBITDA?

ZyVersa Therapeutics Inc (ZVSA) had EBITDA of -$25.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is ZyVersa Therapeutics Inc's operating cash flow?

ZyVersa Therapeutics Inc (ZVSA) generated -$5.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are ZyVersa Therapeutics Inc's total assets?

ZyVersa Therapeutics Inc (ZVSA) had $348K in total assets as of fiscal year 2025, including both current and long-term assets.

How much does ZyVersa Therapeutics Inc spend on research and development?

ZyVersa Therapeutics Inc (ZVSA) invested $1.1M in research and development during fiscal year 2025.

How many shares does ZyVersa Therapeutics Inc have outstanding?

ZyVersa Therapeutics Inc (ZVSA) had 8M shares outstanding as of fiscal year 2025.

What is ZyVersa Therapeutics Inc's current ratio?

ZyVersa Therapeutics Inc (ZVSA) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is ZyVersa Therapeutics Inc's debt-to-equity ratio?

ZyVersa Therapeutics Inc (ZVSA) had a debt-to-equity ratio of -1.03 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ZyVersa Therapeutics Inc's return on assets (ROA)?

ZyVersa Therapeutics Inc (ZVSA) had a return on assets of -7172.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is ZyVersa Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, ZyVersa Therapeutics Inc (ZVSA) had $1.5M in cash against an annual operating cash burn of $5.1M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is ZyVersa Therapeutics Inc's debt-to-equity ratio negative or unusual?

ZyVersa Therapeutics Inc (ZVSA) has negative shareholder equity of -$12.4M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is ZyVersa Therapeutics Inc's Piotroski F-Score?

ZyVersa Therapeutics Inc (ZVSA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ZyVersa Therapeutics Inc's earnings high quality?

ZyVersa Therapeutics Inc (ZVSA) has an earnings quality ratio of 0.20x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can ZyVersa Therapeutics Inc cover its interest payments?

ZyVersa Therapeutics Inc (ZVSA) has an interest coverage ratio of -49.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.